Litcius/Paper detail

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA

Prajakta P. Masurkar, Haluk Damgacioglu, Ashish A. Deshmukh, Meghana V. Trivedi

2023PharmacoEconomics25 citationsDOI

Topics & Concepts

PalbociclibLetrozoleMedicineMetastatic breast cancerBreast cancerOncologyInternal medicineFulvestrantCancerTamoxifenAdvanced Breast Cancer TherapiesBRCA gene mutations in cancerHER2/EGFR in Cancer Research
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA | Litcius